Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
12.60
+1.08 (9.38%)
Feb 4, 2025, 4:00 PM EST - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 21.83, with a low estimate of 13 and a high estimate of 35. The average target predicts an increase of 73.25% from the current stock price of 12.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 | Strong Buy | Maintains | $35 | +177.78% | Jan 8, 2025 |
| Needham | Needham | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +74.60% | Jan 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +90.48% | Dec 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +177.78% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
18.04M
from 8.78M
Increased by 105.42%
Revenue Next Year
15.56M
from 18.04M
Decreased by -13.71%
EPS This Year
-2.07
from -2.38
EPS Next Year
-2.50
from -2.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 19.8M | 47.3M | 72.5M | |||
| Avg | 18.0M | 15.6M | 24.9M | |||
| Low | 13.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 126.0% | 162.0% | 365.8% | |||
| Avg | 105.4% | -13.7% | 60.1% | |||
| Low | 55.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.08 | -2.18 | -2.19 | |||
| Avg | -2.07 | -2.50 | -2.56 | |||
| Low | -2.07 | -2.76 | -2.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.